drugset / Trial / NCT07010237

Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia

NCT07010237

NaSingle-groupOpen-labelTreatment

Summary

This is a prospetive,Single-Center, Single-Arm, Phase IIB Clinical Study.This study aims to evaluate the efficacy and safety of dose-attenuated IST combined with Hetrombopag in elderly patients (≥65 years) with VSAA/SAA.

Timeline

Start
2025-02-01
Primary completion
2028-12-31
Completion
2029-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 3 mg/kg
Subject Hetrombopag Small molecule 15 mg
Subject Porcine-ATG Unknown 15 mg/kg Intravenous

Indications